Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 240 articles:
HTML format
Text format



Single Articles


    February 2019
  1. KE Y, Taylor J, Gao LL, Wang H, et al
    Twitter Response to the 2018 United States Preventive Services Task Force Guidelines on Prostate Cancer Screening.
    BJU Int. 2019 Feb 27. doi: 10.1111/bju.14734.
    PubMed     Text format     Abstract available


  2. LOPCI E, Piccardo A, Lazzeri M
    Prostate cancer imaging and therapeutic alternatives with highly specific molecular "probes".
    BJU Int. 2019 Feb 20. doi: 10.1111/bju.14713.
    PubMed     Text format     Abstract available


  3. SATHIANATHEN NJ, Philippou YA, Kuntz GM, Konety BR, et al
    Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: A Cochrane Review.
    BJU Int. 2019 Feb 14. doi: 10.1111/bju.14711.
    PubMed     Text format     Abstract available


  4. STABILE A, Orczyk C, Hosking-Jervis F, Giganti F, et al
    Medium term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using HIFU for primary localized prostate cancer.
    BJU Int. 2019 Feb 12. doi: 10.1111/bju.14710.
    PubMed     Text format     Abstract available


  5. MERRIEL SWD, Hetherington L, Seggie A, Castle JT, et al
    Best practice in Active Surveillance for men with prostate cancer: A Prostate Cancer UK consensus statement.
    BJU Int. 2019 Feb 11. doi: 10.1111/bju.14707.
    PubMed     Text format     Abstract available


  6. GLASS AS, Dall'Era MA
    Use of Multi-Parametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
    BJU Int. 2019 Feb 11. doi: 10.1111/bju.14705.
    PubMed     Text format     Abstract available


  7. LIGHT A, Elhage O, Marconi L, Dasgupta P, et al
    Prostate cancer screening: where are we now?
    BJU Int. 2019 Feb 5. doi: 10.1111/bju.14692.
    PubMed     Text format     Abstract available


  8. KAM J, Yuminaga Y, Krelle M, Gavin D, et al
    How accurate is multi-parametric MRI for predicting prostate cancer pathology and tumour staging in the real world? - An Australian multi-centre study.
    BJU Int. 2019 Feb 3. doi: 10.1111/bju.14696.
    PubMed     Text format     Abstract available


  9. KRIMPHOVE MJ, Fletcher SA, Trinh QD
    Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect real-world practice?
    BJU Int. 2019;123:197-198.
    PubMed     Text format    


  10. ROSE BS
    Postoperative radiation and hormonal therapy for men with node-positive prostate cancer: a new standard?
    BJU Int. 2019;123:199-200.
    PubMed     Text format    


    January 2019
  11. SIMOPOULOS DN, Sisk AE Jr, Priester A, Felker ER, et al
    Cancer Core Length from Targeted Biopsy: An Index of Prostate Cancer Volume and Pathologic Stage.
    BJU Int. 2019 Jan 29. doi: 10.1111/bju.14691.
    PubMed     Text format     Abstract available


  12. ANING JJ, Reilly GS, Fowler S, Challacombe B, et al
    Peri-operative and oncological outcomes of radical prostatectomy for high-risk prostate cancer in the UK: an analysis of surgeon reported data.
    BJU Int. 2019 Jan 25. doi: 10.1111/bju.14687.
    PubMed     Text format     Abstract available


  13. SIGHINOLFI MC, Sandri M, Torricelli P, Ligabue G, et al
    External validation of a novel side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer: preliminary outcomes on a series diagnosed with mpMRI targeted plus systematic sa
    BJU Int. 2019 Jan 18. doi: 10.1111/bju.14665.
    PubMed     Text format     Abstract available


  14. REICHARD CA, Nyame YA, Sundi D, Tosoian J, et al
    Does time from diagnosis to treatment of high or very high risk prostate cancer affect outcome?
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14671.
    PubMed     Text format     Abstract available


  15. MA WK, Poon DM, Chan CK, Chan TW, et al
    Consensus statements on the management of clinically localised prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14681.
    PubMed     Text format     Abstract available


  16. ROBINSON D, Garmo H, Van Hemelrijck M, Damber JE, et al
    Androgen deprivation therapy for prostate cancer and risk of dementia.
    BJU Int. 2019 Jan 13. doi: 10.1111/bju.14666.
    PubMed     Text format     Abstract available


  17. OMLIN A, Gillessen S
    The Advanced Prostate Cancer Consensus on a regional level - what can we learn?
    BJU Int. 2019;123:3-4.
    PubMed     Text format    


    December 2018
  18. GUPTA N, Bivalacqua TJ, Han M, Gorin MA, et al
    Evaluating the Impact of Length of Time from Diagnosis to Surgery in Patients with Unfavorable Intermediate to Very High-Risk Clinically Localized Prostate Cancer.
    BJU Int. 2018 Dec 20. doi: 10.1111/bju.14659.
    PubMed     Text format     Abstract available


  19. YANG YJ, Kong YY, Li GX, Wang Y, et al
    Phenotypes of Circulating Tumor Cells Predict Time to Castration Resistance in Metastatic Castration-Sensitive Prostate Cancer.
    BJU Int. 2018 Dec 7. doi: 10.1111/bju.14642.
    PubMed     Text format     Abstract available


  20. ROCCO B, Sighinolfi MC, Sandri M, Puliatti S, et al
    A novel nomogram for predicting ECE of prostate cancer.
    BJU Int. 2018;122:916-918.
    PubMed     Text format    


    November 2018
  21. GNANAPRAGASAM V, Barrett T, Massie C, Pacey S, et al
    Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.
    BJU Int. 2018 Nov 30. doi: 10.1111/bju.14637.
    PubMed     Text format     Abstract available


  22. CHANDRASEKAR T, Dall'Era MA, Tilki D
    Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer.
    BJU Int. 2018;122:721-722.
    PubMed     Text format    


    October 2018
  23. ORCZYK C, Villers A, Rusinek H, Lepennec V, et al
    Prostate cancer heterogeneity: texture analysis score based on multiple MRI sequences for detection, stratification and selection of lesions at time of biopsy.
    BJU Int. 2018 Oct 30. doi: 10.1111/bju.14603.
    PubMed     Text format     Abstract available


  24. COLLINS A, Sundararajan V, Millar J, Burchell J, et al
    The trajectory of people who die from metastatic prostate cancer: A population-based study.
    BJU Int. 2018 Oct 29. doi: 10.1111/bju.14593.
    PubMed     Text format     Abstract available


  25. ONG WL, Yaxley JW, Millar JL
    Brachytherapy-based radiotherapy with androgen deprivation for management of high-risk prostate cancer - time to reverse the declining trend?
    BJU Int. 2018 Oct 19. doi: 10.1111/bju.14487.
    PubMed     Text format    


  26. VARMA M, Cochlin D, Delahunt B, Kynaston H, et al
    TNM clinical staging of prostate cancer: Issues and solutions.
    BJU Int. 2018 Oct 13. doi: 10.1111/bju.14589.
    PubMed     Text format     Abstract available


  27. GIELCHINSKY I, Chang J, Cusick T, Delprado W, et al
    Prostate Cancer in 432 men under the age of 50 years in the Prostate Specific Antigen era - a new outlook.
    BJU Int. 2018 Oct 10. doi: 10.1111/bju.14586.
    PubMed     Text format     Abstract available


  28. PINSKY PF, Miller E, Prorok P, Grubb R, et al
    Extended follow-up for prostate cancer incidence and mortality in the PLCO randomized cancer screening trial.
    BJU Int. 2018 Oct 5. doi: 10.1111/bju.14580.
    PubMed     Text format     Abstract available


  29. WARNER EW, Yip SM, Chi KN, Wyatt AW, et al
    DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
    BJU Int. 2018 Oct 3. doi: 10.1111/bju.14576.
    PubMed     Text format     Abstract available


  30. TORRES-ROMAN JS, Ruiz EF, Martinez-Herrera JF, Mendes Braga SF, et al
    Prostate Cancer Mortality rates in Peru and its geographic regions.
    BJU Int. 2018 Oct 3. doi: 10.1111/bju.14578.
    PubMed     Text format     Abstract available


    September 2018
  31. CAZZANIGA W, Garmo H, Robinson D, Holmberg L, et al
    Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.
    BJU Int. 2018 Sep 25. doi: 10.1111/bju.14563.
    PubMed     Text format     Abstract available


  32. KAYE DR, Qi J, Morgan TM, Linsell S, et al
    Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    BJU Int. 2018 Sep 24. doi: 10.1111/bju.14554.
    PubMed     Text format     Abstract available


  33. VAN NIEUWENHOVE S, Saussez TP, Thiry S, Trefois P, et al
    Prospective comparison of a fast 1.5T biparametric to the 3.0T multi-parametric ESUR magnetic resonance imaging protocol as triage test for men at risk of prostate cancer.
    BJU Int. 2018 Sep 21. doi: 10.1111/bju.14538.
    PubMed     Text format     Abstract available


  34. STEUBER T, Tennstedt P, Macagno A, Athanasiou A, et al
    Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14540.
    PubMed     Text format     Abstract available


  35. VAN ROMPAY MI, Nickel JC, Ranganathan G, Kantoff PW, et al
    Impact of 5alpha-Reductase Inhibitors and alpha-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14534.
    PubMed     Text format     Abstract available


  36. JAMES ND
    Prognostic and predictive models in hormone-sensitive prostate cancer.
    BJU Int. 2018;122:352-353.
    PubMed     Text format    


  37. HUGHES SR
    2018: A Spacer Odyssey.
    BJU Int. 2018;122:353-354.
    PubMed     Text format    


    August 2018
  38. WISSING M, Brimo F, Chevalier S, Scarlata E, et al
    Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14512.
    PubMed     Text format     Abstract available


  39. SHAH PH, Patel VR, Moreira DM, George AK, et al
    Implementation of Multiparametric Magnetic Resonance Imaging Technology for Evaluation of Patients with Suspicion for Prostate Cancer in the Clinical Practice Setting.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14515.
    PubMed     Text format     Abstract available


  40. JUNG JH, Risk MC, Goldfarb R, Reddy B, et al
    Primary cryotherapy for localised or locally advanced prostate cancer.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14519.
    PubMed     Text format     Abstract available


  41. FENIOUX C, Louvet C, Charton E, Rozet F, et al
    Switch from Abiraterone + Prednisone to Abiraterone + Dexamethasone at asymptomatic PSA progression in metastatic castration-resistant prostate cancer (mCRPC) patients.
    BJU Int. 2018 Aug 11. doi: 10.1111/bju.14511.
    PubMed     Text format     Abstract available


  42. CARLES J, Pichler A, Korunkova H, Tomova A, et al
    Observational, multicenter study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
    BJU Int. 2018 Aug 11. doi: 10.1111/bju.14509.
    PubMed     Text format     Abstract available


  43. VAN LEEUWEN PJ, Donswijk M, Nandurkar R, Stricker P, et al
    68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer.
    BJU Int. 2018 Aug 3. doi: 10.1111/bju.14506.
    PubMed     Text format     Abstract available



  44. NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: (c) NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression.
    BJU Int. 2018;122:173-180.
    PubMed     Text format    


  45. CULIG Z
    The way towards understanding possible multiple functions of AR V7 in prostate cancer.
    BJU Int. 2018;122:169.
    PubMed     Text format    


  46. THOMPSON JE, Stricker PD
    MRI improves active surveillance of prostate cancer however biopsy is still crucial.
    BJU Int. 2018;122:E1-E2.
    PubMed     Text format    



  47. Abstracts of the 19th Asia-Pacific Prostate Cancer Conference 2018, 22 - 25 August 2018, Brisbane, Australia.
    BJU Int. 2018;122 Suppl 2:23-38.
    PubMed     Text format    


  48. CACCIAMANI G, Medina L, Ashrafi A, Landsberger H, et al
    Transvesical robot-assisted simple prostatectomy with 360 degrees circumferential reconstruction: step-by-step technique.
    BJU Int. 2018;122:344-348.
    PubMed     Text format     Abstract available


  49. MAXEINER A, Kittner B, Blobel C, Wiemer L, et al
    Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
    BJU Int. 2018;122:211-218.
    PubMed     Text format     Abstract available


  50. KNAAPILA J, Kallio H, Hakanen AJ, Syvanen K, et al
    Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study.
    BJU Int. 2018;122:203-210.
    PubMed     Text format     Abstract available


  51. HUYNH LM, Osann K, Skarecky D, Ahlering TE, et al
    Predictive modelling of 2-year potency outcomes using a novel 90-day erection fullness scale after robot-assisted radical prostatectomy.
    BJU Int. 2018;122:249-254.
    PubMed     Text format     Abstract available


    July 2018
  52. SCAILTEUX LM, Rioux-Leclercq N, Vincendeau S, Balusson F, et al
    Use of 5alpha-reductase inhibitors for benign prostate hypertrophy and risk of high-grade prostate cancer: A French population-based study.
    BJU Int. 2018 Jul 19. doi: 10.1111/bju.14495.
    PubMed     Text format     Abstract available


  53. CHIONG E, Murphy DG, Akaza H, Buchan NC, et al
    Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    BJU Int. 2018 Jul 18. doi: 10.1111/bju.14489.
    PubMed     Text format     Abstract available


  54. PAK S, Park S, Kim M, Go H, et al
    The impact on oncologic outcomes after radical prostatectomy for prostate cancer of converting soft tissue margins at the apex and bladder neck from tumor positive to negative.
    BJU Int. 2018 Jul 6. doi: 10.1111/bju.14480.
    PubMed     Text format     Abstract available


  55. DAHRAN N, Szewczyk-Bieda M, Vinnicombe S, Fleming S, et al
    Periprostatic Fat Adipokines Expression Correlated with Prostate Cancer Aggressiveness in Men Undergoing Radical Prostatectomy for Clinically Localised Disease.
    BJU Int. 2018 Jul 3. doi: 10.1111/bju.14469.
    PubMed     Text format     Abstract available


  56. POPERT R
    Systematic transperineal and magnetic resonance imaging-targeted biopsies: the resolution of uncertainty.
    BJU Int. 2018;122:6-7.
    PubMed     Text format    


  57. LAVIANA AA, Penson DF
    Multiparametric magnetic resonance imaging (MRI) with targeted fusion biopsy: is the time now?
    BJU Int. 2018;122:1-2.
    PubMed     Text format    


  58. DE NUNZIO C, Lombardo R, Nacchia A, Tema G, et al
    Repeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer.
    BJU Int. 2018;122:83-88.
    PubMed     Text format     Abstract available


    June 2018
  59. STONE NN, Stock RG
    Stage T3b prostate cancer diagnosed with seminal vesicle biopsy and treated by neoadjuvant hormone therapy, permanent brachytherapy and external beam irradiation.
    BJU Int. 2018 Jun 29. doi: 10.1111/bju.14464.
    PubMed     Text format     Abstract available


  60. ELLIOTT D, Hamdy FC, Leslie TA, Rosario D, et al
    Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation versus radical prostatectomy for unilateral localised prostate cancer.
    BJU Int. 2018 Jun 11. doi: 10.1111/bju.14432.
    PubMed     Text format     Abstract available


  61. KUANG AG, Nickel JC, Andriole GL, Castro-Santamaria R, et al
    Both acute and chronic inflammation are associated with lower perineural invasion in men with prostate cancer on repeat biopsy.
    BJU Int. 2018 Jun 6. doi: 10.1111/bju.14428.
    PubMed     Text format     Abstract available


  62. SOOD A, Abdollah F, Menon M
    Robot-assisted radical prostatectomy and a parachute.
    BJU Int. 2018;121:820-821.
    PubMed     Text format    


    May 2018
  63. OTTI VC, Miller C, Powell RJ, Thomas RM, et al
    The diagnostic accuracy of multiparametric MRI prior to biopsy in the detection of prostate cancer.
    BJU Int. 2018 May 27. doi: 10.1111/bju.14420.
    PubMed     Text format     Abstract available


  64. BANCROFT EK, Saya S, Page EC, Myhill K, et al
    The psychosocial impact of undergoing prostate cancer screening for men with BRCA1/2 mutations.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14412.
    PubMed     Text format     Abstract available


  65. SZARVAS T, Sevcenco S, Modos O, Keresztes D, et al
    MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14415.
    PubMed     Text format     Abstract available


  66. KOVAC E, Vertosick EA, Sjoberg DD, Vickers AJ, et al
    Effects of Pathologic Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in men with Clinical Low-risk Prostate Cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14418.
    PubMed     Text format     Abstract available


  67. LOEB S, Taneja S, Walter D, Zweifach S, et al
    Crowd-Funding for Prostate Cancer and Breast Cancer.
    BJU Int. 2018 May 22. doi: 10.1111/bju.14408.
    PubMed     Text format     Abstract available


  68. ALI A, Hoyle A, Mistry H, Clarke NW, et al
    The importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
    BJU Int. 2018 May 19. doi: 10.1111/bju.14400.
    PubMed     Text format     Abstract available


  69. GANDAGLIA G, van den Bergh RCN, Tilki D, Fossati N, et al
    How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14391.
    PubMed     Text format     Abstract available


  70. ZHAO J, Sun G, Liao B, Zhang X, et al
    Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone-metastatic prostate cancer.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14398.
    PubMed     Text format     Abstract available


  71. ISHIOKA J, Matsuoka Y, Uehara S, Yasuda Y, et al
    Computer-aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14397.
    PubMed     Text format     Abstract available


  72. HAJILI T, Ohlmann CH, Linxweiler J, Niklas C, et al
    Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: Results of a single-institution series with long-term follow up.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14393.
    PubMed     Text format     Abstract available


  73. NEWTON RU, Jeffery E, Galvao DA, McIntyre C, et al
    Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen deprivation therapy.
    BJU Int. 2018 May 11. doi: 10.1111/bju.14384.
    PubMed     Text format     Abstract available


  74. HOFMAN MS, Murphy DG, Williams SG, Nzenza T, et al
    A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    BJU Int. 2018 May 3. doi: 10.1111/bju.14374.
    PubMed     Text format     Abstract available


  75. EMBERTON M
    Has tailored, tissue-selective tumour ablation in men with prostate cancer come of age?
    BJU Int. 2018;121:676-677.
    PubMed     Text format    


  76. VENTIMIGLIA E, Briganti A, Montorsi F
    Lymph node dissection during radical prostatectomy for prostate cancer: extending the template in the right patients without increasing complications.
    BJU Int. 2018;121:677-678.
    PubMed     Text format    


  77. REYNOLDS BR, Bulsara C, Zeps N, Codde J, et al
    Exploring pathways towards improving patient experience of robot-assisted radical prostatectomy (RARP): assessing patient satisfaction and attitudes.
    BJU Int. 2018;121 Suppl 3:33-39.
    PubMed     Text format     Abstract available


  78. MISCHINGER J, Kaufmann S, Russo GI, Harland N, et al
    Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2018;121:791-798.
    PubMed     Text format     Abstract available


  79. MADERTHANER L, Furrer MA, Studer UE, Burkhard FC, et al
    More extended lymph node dissection template at radical prostatectomy detects metastases in the common iliac region and in the fossa of Marcille.
    BJU Int. 2018;121:725-731.
    PubMed     Text format     Abstract available


    April 2018
  80. BRIZMOHUN APPAYYA M, Adshead J, Ahmed HU, Allen C, et al
    National Implementation of multi-parametric MRI for prostate cancer detection - Recommendations from a UK consensus meeting.
    BJU Int. 2018 Apr 26. doi: 10.1111/bju.14361.
    PubMed     Text format     Abstract available


  81. SCHOOTS IG, Nieboer D, Giganti F, Moore CM, et al
    Is MRI-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
    BJU Int. 2018 Apr 21. doi: 10.1111/bju.14358.
    PubMed     Text format     Abstract available


  82. MARTINI A, Gupta A, Lewis SC, Cumarasamy S, et al
    Development and Internal Validation of a Side Specific, Multiparametric MRI-based Nomogram for the Prediction of Extracapsular Extension of Prostate Cancer.
    BJU Int. 2018 Apr 19. doi: 10.1111/bju.14353.
    PubMed     Text format     Abstract available


  83. BRYANT RJ, Yang B, Philippou Y, Lam K, et al
    Does the introduction of prostate multiparametric MRI into active surveillance of localised prostate cancer improve patient re-classification?
    BJU Int. 2018 Apr 12. doi: 10.1111/bju.14248.
    PubMed     Text format     Abstract available


  84. CASH H, Steiner U, Heidenreich A, Klotz T, et al
    Intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration resistant prostate cancer (CRPC) - a phase III study (PRINCE).
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14239.
    PubMed     Text format     Abstract available


  85. LANCEE M, Tikkinen KAO, de Reijke TM, Kataja VV, et al
    Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14237.
    PubMed     Text format     Abstract available


  86. EBBINGE M, Berglund A, Varenhorst E, Hedlund PO, et al
    Clinical and Prognostic Significance of Changes in Haemoglobin Level During One Year of Androgen Deprivation Treatment for Hormone-Naive Bone Metastatic Prostate Cancer.
    BJU Int. 2018 Apr 2. doi: 10.1111/bju.14227.
    PubMed     Text format     Abstract available


  87. HARMOUCH SS, Berger AJ, Cole AP
    Low rates of bone density testing in prostate cancer survivors on androgen-deprivation therapy: where do we go from here?
    BJU Int. 2018;121:492-493.
    PubMed     Text format    


  88. KLOTZ L
    Prostate cancer prevention: proof is elusive.
    BJU Int. 2018;121:487-488.
    PubMed     Text format    


  89. LAING R, Uribe J, Uribe-Lewis S, Money-Kyrle J, et al
    LDR brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
    BJU Int. 2018 Apr 1. doi: 10.1111/bju.14223.
    PubMed     Text format     Abstract available


  90. BANDINI M, Marchioni M, Pompe RS, Tian Z, et al
    First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy.
    BJU Int. 2018;121:592-599.
    PubMed     Text format     Abstract available


    March 2018
  91. VATANDOUST S, Kichenadasse G, O'Callaghan M, Vincent AD, et al
    Localized prostate cancer in elderly men aged 80-89, findings from a population-based registry.
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14228.
    PubMed     Text format     Abstract available


  92. ANSMANN L, Winter N, Ernstmann N, Heidenreich A, et al
    Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW).
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14215.
    PubMed     Text format     Abstract available


  93. STATTIN P, Sandin F, Loeb S, Robinson D, et al
    Public online reporting from a nationwide population-based clinical prostate cancer register.
    BJU Int. 2018 Mar 25. doi: 10.1111/bju.14213.
    PubMed     Text format     Abstract available


  94. CHEN R, Dong X, Gleave M
    Molecular Model for Neuroendocrine Prostate Cancer Progression.
    BJU Int. 2018 Mar 22. doi: 10.1111/bju.14207.
    PubMed     Text format     Abstract available


  95. AUBERTIN K, Trinh VQ, Jermyn M, Baksic P, et al
    Mesoscopic characterization of prostate cancer using Raman spectroscopy: Potential for diagnostics and therapeutics.
    BJU Int. 2018 Mar 15. doi: 10.1111/bju.14199.
    PubMed     Text format     Abstract available


  96. RUSSO GI, Bier S, Hennenlotter J, Beger G, et al
    Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    BJU Int. 2018 Mar 15. doi: 10.1111/bju.14200.
    PubMed     Text format     Abstract available


  97. VIDAL AC, Howard LE, de Hoedt A, Kane CJ, et al
    Obese Castration-Resistant Prostate Cancer Patients may be at a lower risk of all-cause mortality: Results from the SEARCH Database.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14193.
    PubMed     Text format     Abstract available


  98. CHAO M, Ho H, Chan Y, Tan A, et al
    Prospective analysis of hydrogel spacer for prostate cancer patients undergoing radiotherapy.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14192.
    PubMed     Text format     Abstract available


  99. COUTURE F, Tholomier C, Zorn KC
    Prostate cancer biochemical recurrence after salvage radiotherapy: first look into risk stratification and prognosis.
    BJU Int. 2018;121:320-321.
    PubMed     Text format    


  100. GHANEM S, Namdarian B, Challacombe B
    To drain or not to drain after robot-assisted radical prostatectomy? That is the question.
    BJU Int. 2018;121:321-322.
    PubMed     Text format    


  101. PALAYAPALAYAM GANAPATHI H, Onol F, Rogers T, Patel V, et al
    Nerve wrapping with biomaterials during radical prostatectomy to improve potency recovery.
    BJU Int. 2018;121:322-323.
    PubMed     Text format    


  102. SATHIANATHEN NJ, Christidis D, Konety BR, Lawrentschuk NL, et al
    Magnetic resonance imaging cognitive fusion biopsy - is near enough good enough?
    BJU Int. 2018;121:324-326.
    PubMed     Text format    


  103. PATEL VR, Sandri M, Grasso AAC, De Lorenzis E, et al
    A novel tool for predicting extracapsular extension during graded partial nerve sparing in radical prostatectomy.
    BJU Int. 2018;121:373-382.
    PubMed     Text format     Abstract available


  104. CHENAM A, Yuh B, Zhumkhawala A, Ruel N, et al
    Prospective randomised non-inferiority trial of pelvic drain placement vs no pelvic drain placement after robot-assisted radical prostatectomy.
    BJU Int. 2018;121:357-364.
    PubMed     Text format     Abstract available


  105. MAI Z, Xiao Y, Yan W, Zhou Y, et al
    Comparison of lesions detected and undetected by template-guided transperineal saturation prostate biopsy.
    BJU Int. 2018;121:415-420.
    PubMed     Text format     Abstract available


  106. PORPIGLIA F, Bertolo R, Fiori C, Manfredi M, et al
    Chitosan membranes applied on the prostatic neurovascular bundles after nerve-sparing robot-assisted radical prostatectomy: a phase II study.
    BJU Int. 2018;121:472-478.
    PubMed     Text format     Abstract available


    February 2018
  107. NASSAR ZD, Aref AT, Miladinovic D, Mah CY, et al
    Peri-Prostatic Adipose Tissue: The metabolic microenvironment of prostate cancer.
    BJU Int. 2018 Feb 20. doi: 10.1111/bju.14173.
    PubMed     Text format     Abstract available


  108. ALTOK M, Babaian K, Achim MF, Achim GC, et al
    Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection.
    BJU Int. 2018 Feb 15. doi: 10.1111/bju.14164.
    PubMed     Text format     Abstract available


  109. BOLTON EM, Lynch TH
    Are all gonadotropin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14168.
    PubMed     Text format     Abstract available


  110. THURTLE D, Barrett T, Thankappan-Nair V, Koo B, et al
    Progression and treatment rates using an active surveillance protocol incorporating image guided baseline biopsies and multi-parametric MRI monitoring for men with favourable risk prostate cancer.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14166.
    PubMed     Text format     Abstract available


  111. SOORIAKUMARAN P
    Surgery for oligometastatic prostate cancer: ready for prime time?
    BJU Int. 2018 Feb 12. doi: 10.1111/bju.14038.
    PubMed     Text format    


  112. WALLIS CJD, Satkunasivam R, Bhindi B
    Selecting patients for prostate cancer treatment: the role of comorbidity.
    BJU Int. 2018;121:164-165.
    PubMed     Text format    


  113. SOLIGO M, Sharma V, Karnes RJ
    Is it time for a more 'proactive' approach to metastatic prostate cancer?
    BJU Int. 2018;121:167-168.
    PubMed     Text format    


  114. BARNETT CL, Davenport MS, Montgomery JS, Wei JT, et al
    Cost-Effectiveness of Magnetic Resonance Imaging and Targeted Fusion Biopsy for Early Detection of Prostate Cancer.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14151.
    PubMed     Text format     Abstract available


  115. GILBERT DC, Duong T, Sydes M, Bara A, et al
    Transdermal Oestradiol as a method of androgen suppression for Prostate Cancer within the STAMPEDE Trial Platform.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14153.
    PubMed     Text format     Abstract available


  116. SONPAVDE G, Huang A, Wang L, Baser O, et al
    Taxane chemotherapy versus anti-androgen agents as first-line therapy for metastatic castration-resistant prostate cancer.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14152.
    PubMed     Text format     Abstract available


  117. HEIDENREICH A, Pfister D
    Even 'low-dose' cabazitaxel requires careful and meticulous patient selection.
    BJU Int. 2018;121:163-164.
    PubMed     Text format    


  118. KENIGSBERG AP, Tamada T, Rosenkrantz AB, Llukani E, et al
    Multiparametric magnetic resonance imaging identifies significant apical prostate cancers.
    BJU Int. 2018;121:239-243.
    PubMed     Text format     Abstract available


  119. AUFFENBERG GB, Qi J, Gao Y, Miller DC, et al
    Evaluation of a needle disinfectant technique to reduce infection-related hospitalisation after transrectal prostate biopsy.
    BJU Int. 2018;121:232-238.
    PubMed     Text format     Abstract available


    January 2018
  120. RUTLEDGE AB, McLeod N, Mehan N, Regan TW, et al
    A clinician-centred program for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14144.
    PubMed     Text format     Abstract available


  121. ABDEL-RAHMAN O, Cheung WY
    External Validation Of The Prostascore Model Among Metastatic Hormone-Sensitive Prostate Cancer Patients Recruited In The CHAARTED Study.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14138.
    PubMed     Text format     Abstract available


  122. LAZAREV S, Thompson MR, Stone NN, Stock RG, et al
    Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10 Years of Follow-Up.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14122.
    PubMed     Text format     Abstract available


  123. SCHLUSSEL MARKOVIC E, Buckstein M, Stone NN, Stock RG, et al
    Outcomes and Toxicities in Intermediate-Risk Prostate Cancer Patients Treated with Brachytherapy Alone or Brachytherapy and Supplemental External Beam Radiation Therapy.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14128.
    PubMed     Text format     Abstract available


  124. FLETCHER SA, Berg S, Trinh QD
    The new frontier of prostate biopsy: determining the role of image-guidance in moving the needle.
    BJU Int. 2018;121:4-5.
    PubMed     Text format    


  125. STONE N
    Low dose rate prostate brachytherapy in younger men.
    BJU Int. 2018;121:2.
    PubMed     Text format    


  126. BORKOWETZ A, Hadaschik B, Platzek I, Toma M, et al
    Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naive patients.
    BJU Int. 2018;121:53-60.
    PubMed     Text format     Abstract available


  127. SHIN T, Smyth TB, Ukimura O, Ahmadi N, et al
    Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI/ultrasonography image-fusion targeted biopsy of the prostate.
    BJU Int. 2018;121:77-83.
    PubMed     Text format     Abstract available


  128. SU J, Zhu Q, Yuan L, Zhang Y, et al
    Transumbilical laparoendoscopic single-site radical prostatectomy and cystectomy with the aid of a transurethral port: a feasibility study.
    BJU Int. 2018;121:111-118.
    PubMed     Text format     Abstract available


    December 2017
  129. NANTON V, Appleton R, Loew J, Ahmed N, et al
    Men don't talk about their health, but will they CHAT? The potential of online holistic needs assessment in prostate cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14114.
    PubMed     Text format     Abstract available


  130. BRUINSMA SM, Zhang L, Roobol MJ, Bangma CH, et al
    The Movember Foundation's GAP3 cohort: A profile of the largest global prostate cancer active surveillance database to date.
    BJU Int. 2017 Dec 15. doi: 10.1111/bju.14106.
    PubMed     Text format     Abstract available


  131. VOSS J, Pal R, Ahmed S, Hannah M, et al
    Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    BJU Int. 2017 Dec 14. doi: 10.1111/bju.14100.
    PubMed     Text format     Abstract available


  132. DRUSKIN SC, Tosoian JJ, Young A, Collica S, et al
    Incorporating Prostate Health Index Density, MRI, and Prior Negative Biopsy Status to Improve the Detection of Clinically Significant Prostate Cancer.
    BJU Int. 2017 Dec 12. doi: 10.1111/bju.14098.
    PubMed     Text format     Abstract available


  133. POON DM, Chan CK, Chan TW, Cheung FY, et al
    Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    BJU Int. 2017 Dec 6. doi: 10.1111/bju.14091.
    PubMed     Text format     Abstract available


  134. PORPIGLIA F, De Luca S
    Prostate cancer biomarkers: new scenarios in the multi-parametric magnetic resonance imaging era.
    BJU Int. 2017;120:745-746.
    PubMed     Text format    


  135. BULTIJNCK R, Van de Caveye I, Rammant E, Everaert S, et al
    Clinical Pathway improves Implementation of Evidence-based Strategies for the management of Androgen Deprivation Therapy-induced side effects in Prostate Cancer Patients.
    BJU Int. 2017 Dec 1. doi: 10.1111/bju.14086.
    PubMed     Text format     Abstract available


  136. BJURLIN MA, Taneja SS
    Novel risk stratification nomograms for counseling patients on the need for prostate biopsy.
    BJU Int. 2017;120:746-747.
    PubMed     Text format    


  137. DASGUPTA P
    NICE guidance and the BJUI.
    BJU Int. 2017;120:743.
    PubMed     Text format    


    November 2017
  138. KIRK PS, Borza T, Shahinian VB, Caram MEV, et al
    The implications of baseline bone health assessment at initiation of androgen deprivation therapy for prostate cancer.
    BJU Int. 2017 Nov 10. doi: 10.1111/bju.14075.
    PubMed     Text format     Abstract available


  139. SIRIWARDANA A, Thompson J, van Leeuwen PJ, Doig S, et al
    Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.
    BJU Int. 2017;120:673-681.
    PubMed     Text format     Abstract available


  140. BOEHM K, Leyh-Bannurah SR, Rosenbaum C, Brandi LS, et al
    Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.
    BJU Int. 2017;120:666-672.
    PubMed     Text format     Abstract available


  141. HANSEN NL, Kesch C, Barrett T, Koo B, et al
    Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
    BJU Int. 2017;120:631-638.
    PubMed     Text format     Abstract available


  142. YAXLEY AJ, Yaxley JW, Thangasamy IA, Ballard E, et al
    Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    BJU Int. 2017;120 Suppl 3:43-50.
    PubMed     Text format     Abstract available


  143. KINNEAR N, Smith R, Hennessey DB, Bolton D, et al
    Implementation rates of uro-oncology multidisciplinary meeting decisions.
    BJU Int. 2017;120 Suppl 3:15-20.
    PubMed     Text format     Abstract available


  144. LOEB S
    Educational intervention in prostate cancer.
    BJU Int. 2017;120.
    PubMed     Text format    


  145. CHALFIN HJ, Pienta KJ, Gorin MA
    Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells.
    BJU Int. 2017;120.
    PubMed     Text format    


  146. STRATTON K
    Cystectomy for cT4 prostate cancer: the most radical treatment.
    BJU Int. 2017;120.
    PubMed     Text format    


  147. EPSTEIN JI
    Central pathology review of radical prostatectomy specimens does make a difference not only with grade.
    BJU Int. 2017;120.
    PubMed     Text format    


    October 2017
  148. GANDAGLIA G, Zaffuto E, Fossati N, Bandini M, et al
    Identifying the candidate for super extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14066.
    PubMed     Text format     Abstract available


  149. ILIC D, Evans SM, Allan CA, Jung JH, et al
    Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer: a Cochrane systematic review.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14062.
    PubMed     Text format     Abstract available


  150. HANSEN NL, Barrett T, Kesch C, Pepdjonovic L, et al
    Multicentre evaluation of Magnetic Resonance Imaging supported transperineal prostate biopsy in biopsy-naive men with suspicion of prostate cancer.
    BJU Int. 2017 Oct 11. doi: 10.1111/bju.14049.
    PubMed     Text format     Abstract available


  151. KLAASSEN Z, Murphy DG
    STAMPEDE-ing Towards Androgen Biosynthesis Inhibition for Treatment of High-Risk Hormone-Naive Prostate Cancer: Changing the LATITUDE.
    BJU Int. 2017 Oct 9. doi: 10.1111/bju.14050.
    PubMed     Text format     Abstract available


  152. FRADET V, Toren P, Nguile-Makao M, Lodde M, et al
    Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5alpha-reductase inhibitors.
    BJU Int. 2017 Oct 3. doi: 10.1111/bju.14041.
    PubMed     Text format     Abstract available


  153. HAMMARSTEN J
    Anomalous observation with regard to prostate cancer in cancer research.
    BJU Int. 2017;120:456-457.
    PubMed     Text format    


  154. ALBERTS AR, Roobol MJ, Drost FH, van Leenders GJ, et al
    Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    BJU Int. 2017;120:511-519.
    PubMed     Text format     Abstract available


  155. LLUKANI E, Lepor H
    Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.
    BJU Int. 2017;120:505-510.
    PubMed     Text format     Abstract available


  156. ZHAO S, Xia M, Tang J, Yan Y, et al
    Actual lowering effect of metabolic syndrome on serum prostate-specific antigen levels is partly concealed by enlarged prostate: results from a large-scale population-based study.
    BJU Int. 2017;120:482-489.
    PubMed     Text format     Abstract available


  157. LOEB S, Stork B, Gold HT, Stout NK, et al
    Tweet this: how advocacy for breast and prostate cancers stacks up on social media.
    BJU Int. 2017;120:461-463.
    PubMed     Text format    


    September 2017
  158. VAN STAM MA, van der Poel HG, van der Voort van Zyp JRN, Tillier CN, et al
    The accuracy of patients' perceptions of the risks associated with localized prostate cancer treatments.
    BJU Int. 2017 Sep 28. doi: 10.1111/bju.14034.
    PubMed     Text format     Abstract available


  159. BLANCHARD P, Davis JW, Frank SJ, Kim J, et al
    Quality of life following brachytherapy or bilateral nerve sparing robotic prostatectomy for prostate cancer: a prospective cohort.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14021.
    PubMed     Text format     Abstract available


  160. RULACH R, McKay S, Neilson S, White L, et al
    Real World Uptake, Safety Profile and Outcomes of Docetaxel in Newly Diagnosed Metastatic Prostate Cancer.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14025.
    PubMed     Text format     Abstract available


  161. BOSCO C, Wong C, Garmo H, Crawley D, et al
    Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14023.
    PubMed     Text format     Abstract available


  162. MARRA G, Dalmasso E, Angello M, Munegato S, et al
    Prostate Cancer Treatment in Renal Transplant Recipients: A Systematic Review.
    BJU Int. 2017 Sep 18. doi: 10.1111/bju.14018.
    PubMed     Text format     Abstract available


  163. POON Y, Pechlivanoglou P, Alibhai SMH, Naimark D, et al
    Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen Deprivation Therapy to Reduce Risk of Fragility Fractures.
    BJU Int. 2017 Sep 18. doi: 10.1111/bju.14015.
    PubMed     Text format     Abstract available


  164. TAAFFE DR, Buffart LM, Newton RU, Spry N, et al
    Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14008.
    PubMed     Text format     Abstract available


  165. LAWRENTSCHUK N, Corfield JM, Scott A
    Is choline-based PET imaging still relevant in recurrent prostate cancer?
    BJU Int. 2017;120:303-304.
    PubMed     Text format    


  166. STEURER S, Rico SD, Simon R, Minner S, et al
    High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.
    BJU Int. 2017;120:365-376.
    PubMed     Text format     Abstract available


  167. JACKSON WC, Desai NB, Abugharib AE, Tumati V, et al
    Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.
    BJU Int. 2017;120:351-357.
    PubMed     Text format     Abstract available


  168. KIM PJ, Park JY, Kim HG, Cho YM, et al
    Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma.
    BJU Int. 2017;120:343-350.
    PubMed     Text format     Abstract available


  169. SUARDI N, Montorsi F
    Salvage lymph node dissection: if yes, robotics?
    BJU Int. 2017;120:304-305.
    PubMed     Text format    


  170. FICARRA V, Novara G, Dasgupta P
    Robot-assisted vs open radical prostatectomy: the day after.
    BJU Int. 2017;120:308-309.
    PubMed     Text format    


    August 2017
  171. SCHELTEMA MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, et al
    Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    BJU Int. 2017 Aug 21. doi: 10.1111/bju.13991.
    PubMed     Text format     Abstract available


  172. JANG WS, Kim MS, Jeong WS, Chang KD, et al
    Does robot-assisted radical prostatectomy benefit prostate cancer patients with bone oligometastases?
    BJU Int. 2017 Aug 21. doi: 10.1111/bju.13992.
    PubMed     Text format     Abstract available


  173. THOMPSON A, Beresford MJ, Sarmah P, Jefferies ER, et al
    Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post STAMPEDE world.
    BJU Int. 2017 Aug 19. doi: 10.1111/bju.13990.
    PubMed     Text format     Abstract available


  174. VAN DEN BOS W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, et al
    Focal irreversible electroporation as primary treatment for localized prostate cancer.
    BJU Int. 2017 Aug 10. doi: 10.1111/bju.13983.
    PubMed     Text format     Abstract available


  175. THALMANN GN, Nguyen DP
    Sentinel nodes in prostate cancer- are we chasing a ghost?
    BJU Int. 2017;120:161-162.
    PubMed     Text format    



  176. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: (c) NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int. 2017;120:168-184.
    PubMed     Text format    


  177. GORIN MA, Pomper MG, Pienta KJ, Rowe SP, et al
    Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer.
    BJU Int. 2017;120:160-161.
    PubMed     Text format    


  178. PAVLOVICH CP, Rocco B, Druskin SC, Davis JW, et al
    Urinary continence recovery after radical prostatectomy - anatomical/reconstructive and nerve-sparing techniques to improve outcomes.
    BJU Int. 2017;120:185-196.
    PubMed     Text format     Abstract available


  179. KADONO Y, Machioka K, Nakashima K, Iijima M, et al
    Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism.
    BJU Int. 2017;120:293-299.
    PubMed     Text format     Abstract available


  180. SUJENTHIRAN A, Charman SC, Parry M, Nossiter J, et al
    Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data.
    BJU Int. 2017;120:219-225.
    PubMed     Text format     Abstract available



  181. Abstracts of the 18th Asia-Pacific Prostate Cancer Conference 2017, Australia, 30 August-02 September 2017.
    BJU Int. 2017;120 Suppl 1:5-23.
    PubMed     Text format    


  182. MCGRATH S, Christidis D, Clarebrough E, Ingle R, et al
    Transperineal prostate biopsy - tips for analgesia.
    BJU Int. 2017;120:164-167.
    PubMed     Text format    


    July 2017
  183. ONG WL, Foroudi F, Evans S, Millar J, et al
    Large institutional variations in androgen deprivation therapy utilization with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    BJU Int. 2017 Jul 27. doi: 10.1111/bju.13969.
    PubMed     Text format     Abstract available


  184. BASOURAKOS SP, Davis JW, Chapin BF, Ward JF, et al
    Baseline and Longitudinal Plasma Caveolin-1 Level as a Biomarker in Active Surveillance for Early Stage Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13963.
    PubMed     Text format     Abstract available


  185. DESS RT, Hartman HE, Aghdam N, Jackson WC, et al
    Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13962.
    PubMed     Text format     Abstract available


  186. LANGLEY SEM, Soares R, Uribe J, Uribe-Lewis S, et al
    Long-term oncological outcomes and toxicity in 597 men </=60 years of age at time of low dose rate brachytherapy for localised prostate cancer.
    BJU Int. 2017 Jul 3. doi: 10.1111/bju.13946.
    PubMed     Text format     Abstract available


  187. BASOURAKOS SP, Hoffman K, Kim J
    Active surveillance in prostate cancer: new efforts, new voices, new hope.
    BJU Int. 2017;120:4-5.
    PubMed     Text format    


  188. SAYYID R, Perlis N, Ahmad A, Evans A, et al
    Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension.
    BJU Int. 2017;120:76-82.
    PubMed     Text format     Abstract available


  189. MOSCHINI M, Sharma V, Gandaglia G, Dell'Oglio P, et al
    Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.
    BJU Int. 2017;120:69-75.
    PubMed     Text format     Abstract available


  190. MAMAWALA MM, Rao K, Landis P, Epstein JI, et al
    Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.
    BJU Int. 2017;120:25-31.
    PubMed     Text format     Abstract available


    June 2017
  191. DE BRUYCKER A, Lambert B, Claeys T, Delrue L, et al
    Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
    BJU Int. 2017 Jun 24. doi: 10.1111/bju.13938.
    PubMed     Text format     Abstract available


  192. SOORIAKUMARAN P
    Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone: a randomised controlled feasibility trial.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13925.
    PubMed     Text format     Abstract available


  193. TUMATI V, Jackson WC, Abugharib AE, Raj G, et al
    Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13926.
    PubMed     Text format     Abstract available


  194. VILLERS A, Flamand V, Arquimedes RC, Puech P, et al
    Robot-assisted partial prostatectomy for anterior prostate cancer: a step-by-step guide.
    BJU Int. 2017;119:968-974.
    PubMed     Text format     Abstract available


  195. DIOLOMBI ML, Epstein JI
    Metastatic potential to regional lymph nodes with Gleason score </=7, including tertiary pattern 5, at radical prostatectomy.
    BJU Int. 2017;119:872-878.
    PubMed     Text format     Abstract available


  196. CAVALLO JA, Tewari AK
    Somatic-autonomic neurorrhaphy for erectile function restoration after radical prostatectomy.
    BJU Int. 2017;119:816-818.
    PubMed     Text format    


    May 2017
  197. HEDDEN L, Wassersug R, Mahovlich S, Pollock P, et al
    Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.
    BJU Int. 2017 May 17. doi: 10.1111/bju.13885.
    PubMed     Text format     Abstract available


  198. CHIU PKF, Alberts AR, Venderbos LDF, Bangma CH, et al
    Additional benefit of using a risk based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2017 May 12. doi: 10.1111/bju.13913.
    PubMed     Text format     Abstract available


  199. TOSOIAN JT, Chappidi MR, Bishoff JT, Freedland SJ, et al
    Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13911.
    PubMed     Text format     Abstract available


  200. GREIMAN AK, Rosoff JS, Prasad SM
    Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13875.
    PubMed     Text format     Abstract available


  201. ZUMSTEG ZS, Zelefsky MJ, Woo KM, Spratt DE, et al
    Unification of favorable intermediate, unfavorable intermediate, and very high risk-stratification criteria for prostate cancer.
    BJU Int. 2017 May 2. doi: 10.1111/bju.13903.
    PubMed     Text format     Abstract available


  202. GANDAGLIA G, Fossati N, Dell'Oglio P, Montorsi F, et al
    Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?
    BJU Int. 2017;119:652-653.
    PubMed     Text format    


  203. TOSOIAN JJ, Chappidi M, Feng Z, Humphreys EB, et al
    Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    BJU Int. 2017;119:676-683.
    PubMed     Text format     Abstract available


  204. FRYDENBERG M
    Reliability of negative multiparametric MRI of the prostate: can we avoid the biopsy? Not yet!
    BJU Int. 2017;119:E9-E10.
    PubMed     Text format    


    April 2017
  205. PROTOPAPA E, van der Meulen J, Moore CM, Smith SC, et al
    Patient Reported Outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13896.
    PubMed     Text format     Abstract available


  206. PARSONS JK, Pierce JP, Mohler J, Paskett E, et al
    The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13890.
    PubMed     Text format     Abstract available


  207. CHIEN GW, Slezak JM, Harrison TN, Jung H, et al
    Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population.
    BJU Int. 2017 Apr 19. doi: 10.1111/bju.13843.
    PubMed     Text format     Abstract available


  208. CRAWLEY D, Garmo H, Rudman S, Stattin P, et al
    Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high risk localised prostate cancer.
    BJU Int. 2017 Apr 18. doi: 10.1111/bju.13880.
    PubMed     Text format     Abstract available


  209. VIOLET JA, Hofman MS
    Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
    BJU Int. 2017 Apr 5. doi: 10.1111/bju.13871.
    PubMed     Text format     Abstract available


  210. EMBERTON M
    An end to the phenomenon of 'upgrading' in early prostate cancer?
    BJU Int. 2017;119:506-507.
    PubMed     Text format    


  211. BAUER RM, Grabbert MT, Klehr B, Gebhartl P, et al
    36-month data for the AdVance XP(R) male sling: results of a prospective multicentre study.
    BJU Int. 2017;119:626-630.
    PubMed     Text format     Abstract available


  212. DAVIS JW, MacLennan G
    The BJUI's clinical trials initiative.
    BJU Int. 2017;119:503.
    PubMed     Text format    


    March 2017
  213. TELANG JM, Lane BR, Cher ML, Miller DC, et al
    Prostate cancer, family history, and eligibility for active surveillance: A systematic review of the literature.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13862.
    PubMed     Text format     Abstract available


  214. DIJKSTRA S, Govers TM, Hendriks RJ, Schalken JA, et al
    Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13861.
    PubMed     Text format     Abstract available


  215. GROGAN J, Gupta R, Mahon KL, Stricker PD, et al
    Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in radical prostatectomy patients with long-term follow up.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13857.
    PubMed     Text format     Abstract available


  216. HOWARD LE, Moreira D, De Hoedt A, Aronson WJ, et al
    Cut-points for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13856.
    PubMed     Text format     Abstract available


  217. CLEMENT-ZHAO A, Auvray M, Aboudagga H, Blanc-Durand F, et al
    Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13855.
    PubMed     Text format     Abstract available


  218. MACLENNAN S, Williamson PR, Bekema H, Campbell M, et al
    A core outcome set for localised prostate cancer effectiveness trials.
    BJU Int. 2017 Mar 27. doi: 10.1111/bju.13854.
    PubMed     Text format     Abstract available


  219. KANDASWAMY GV, Bennett A, Narahari K, Hughes O, et al
    Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate risk localised prostate cancer - results from a large contemporaneous cohort.
    BJU Int. 2017 Mar 20. doi: 10.1111/bju.13850.
    PubMed     Text format     Abstract available


  220. BALL MW, Harris KT, Schwen ZR, Mullins JK, et al
    Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series.
    BJU Int. 2017;119:444-448.
    PubMed     Text format     Abstract available


  221. GETTMAN MT
    Rethinking cancer surveillance with shared-care models and survivorship plans: the time is now!
    BJU Int. 2017;119:360-361.
    PubMed     Text format    


    February 2017
  222. FICARRA V, Crestani A, Rossanese M, Palumbo V, et al
    Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy.
    BJU Int. 2017;119:245-253.
    PubMed     Text format     Abstract available


  223. MATHIEU R, Lucca I, Vartolomei MD, Mbeutcha A, et al
    Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
    BJU Int. 2017;119:234-238.
    PubMed     Text format     Abstract available


  224. WASHINO S, Okochi T, Saito K, Konishi T, et al
    Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients.
    BJU Int. 2017;119:225-233.
    PubMed     Text format     Abstract available


    January 2017
  225. SANTOK GD, Abdel Raheem A, Kim LH, Chang K, et al
    Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size.
    BJU Int. 2017;119:135-141.
    PubMed     Text format     Abstract available


  226. ZARGAR H, van den Bergh R, Moon D, Lawrentschuk N, et al
    The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    BJU Int. 2017;119:110-115.
    PubMed     Text format     Abstract available


  227. DANNEMAN D, Drevin L, Delahunt B, Samaratunga H, et al
    Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.
    BJU Int. 2017;119:50-56.
    PubMed     Text format     Abstract available


  228. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
    BJU Int. 2017;119:57-66.
    PubMed     Text format     Abstract available


  229. TOSOIAN JJ, Epstein JI
    Prognostic value of prostate biopsy grade: forever a product of sampling.
    BJU Int. 2017;119:5-7.
    PubMed     Text format    


  230. PERERA M, Katelaris N, Murphy DG, McGrath S, et al
    Prostate Imaging Reporting and Data System score of four or more: active surveillance no more.
    BJU Int. 2017;119:9-12.
    PubMed     Text format    


    October 2016
  231. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Text format     Abstract available


  232. DEVECI S, Gotto GT, Alex B, O'Brien K, et al
    A survey of patient expectations regarding sexual function following radical prostatectomy.
    BJU Int. 2016;118:641-5.
    PubMed     Text format     Abstract available


  233. WYSOCK JS, Mendhiratta N, Zattoni F, Meng X, et al
    Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
    BJU Int. 2016;118:515-20.
    PubMed     Text format     Abstract available


  234. MURRAY NP, Aedo S, Reyes E, Orellana N, et al
    Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    BJU Int. 2016;118:556-62.
    PubMed     Text format     Abstract available


    June 2016
  235. ANDERSON CB, Tin AL, Sjoberg DD, Mulhall JP, et al
    Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  236. DE NUNZIO C, Presicce F, Lombardo R, Cancrini F, et al
    Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  237. DINH KT, Mahal BA, Ziehr DR, Muralidhar V, et al
    Risk of prostate cancer mortality in men with a history of prior cancer.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  238. WATSON E, Shinkins B, Frith E, Neal D, et al
    Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


    June 2015
  239. PARK J, Cho SY, Jeong SH, Lee SB, et al
    Low testosterone level is an independent risk factor for high-grade prostate cancer detection via biopsy.
    BJU Int. 2015 Jun 18. doi: 10.1111/bju.13206.
    PubMed     Text format     Abstract available


    May 2015
  240. CARLSSON S, Drevin L, Loeb S, Widmark A, et al
    Population-based study of long-term functional outcomes after prostate cancer treatment.
    BJU Int. 2015 May 8. doi: 10.1111/bju.13179.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: